Anzeige
Mehr »
Dienstag, 20.01.2026 - Börsentäglich über 12.000 News
98,7% Goldausbeute ohne Cyanid - kommt jetzt der Milliarden-Deal?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CM1G | ISIN: US95075A1079 | Ticker-Symbol:
NASDAQ
16.01.26 | 21:59
0,554 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
WEREWOLF THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
WEREWOLF THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur WEREWOLF THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
WEREWOLF THERAPEUTICS Aktie jetzt für 0€ handeln
19.12.25H.C. Wainwright senkt Kursziel für Werewolf Therapeutics nach Pipeline-Update drastisch14
19.12.25H.C. Wainwright slashes Werewolf Therapeutics stock price target on pipeline update2
18.12.25Werewolf Therapeutics, Inc. - 8-K, Current Report12
04.11.25Werewolf Therapeutics reports Q3 results10
04.11.25Werewolf Therapeutics, Inc. - 10-Q, Quarterly Report1
04.11.25Werewolf Therapeutics, Inc. - 8-K, Current Report1
08.10.25Werewolf Therapeutics Says FDA Grants Fast Track For WTX-124 In Advanced Melanoma Treatment4
08.10.25Werewolf Therapeutics receives FDA Fast Track for melanoma therapy3
08.10.25Werewolf Therapeutics, Inc.: Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer339Fast Track Designation underscores the promise of Werewolf's INDUKINE platform WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq:...
► Artikel lesen
06.10.25Todesfall im Verwaltungsrat: Werewolf Therapeutics erfüllt NASDAQ-Regeln für Prüfungsausschuss nicht mehr8
06.10.25Werewolf Therapeutics, Inc. - 8-K, Current Report1
03.10.25Werewolf Therapeutics, Inc.: Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting2
21.08.25Citizens JMP lowers Werewolf Therapeutics stock price target to $3 from $45
14.08.25Werewolf Therapeutics, Inc. - 10-Q, Quarterly Report4
14.08.25Werewolf Therapeutics, Inc. - 8-K, Current Report3
06.08.25Werewolf Therapeutics celebrates 'Full Moon Moments' in clinical trial recruitment push6
08.05.25Werewolf Therapeutics, Inc.: Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update380- WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year - - First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking...
► Artikel lesen
17.04.25Werewolf Therapeutics, Inc.: Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer477WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
► Artikel lesen
11.03.25Werewolf Therapeutics, Inc.: Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update490- Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1